At the time of writing, Skye Bioscience Inc [SKYE] stock is trading at $3.5, up 0.57%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The SKYE shares have gain 6.38% over the last week, with a monthly amount drifted -1.96%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Skye Bioscience Inc [NASDAQ: SKYE] stock has seen the most recent analyst activity on August 15, 2025, when Evercore ISI initiated its Outperform rating and assigned the stock a price target of $10. On September 30, 2024, Scotiabank initiated with a Sector Outperform rating and assigned a price target of $20 on the stock. JMP Securities started tracking the stock assigning a Mkt Outperform rating and suggested a price target of $15 on September 10, 2024. Craig Hallum initiated its recommendation with a Buy and recommended $18 as its price target on July 09, 2024. Cantor Fitzgerald started tracking with a Overweight rating for this stock on May 23, 2024, and assigned it a price target of $21. In a note dated April 12, 2024, Oppenheimer initiated an Outperform rating and provided a target price of $25 on this stock.
For the past year, the stock price of Skye Bioscience Inc fluctuated between $1.14 and $7.11. Currently, Wall Street analysts expect the stock to reach $19 within the next 12 months. Skye Bioscience Inc [NASDAQ: SKYE] shares were valued at $3.5 at the most recent close of the market. An investor can expect a potential return of 442.86% based on the average SKYE price forecast.
Analyzing the SKYE fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.81, Equity is -0.69 and Total Capital is -1.14. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.39 points at the first support level, and at 3.28 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.61, and for the 2nd resistance point, it is at 3.71.
Ratios To Look Out For
It is important to note that Skye Bioscience Inc [NASDAQ:SKYE] has a current ratio of 6.09. Further, the Quick Ratio stands at 6.09, while the Cash Ratio is 2.87.
Transactions by insiders
Recent insider trading involved Schwab Andrew J., Director, that happened on Aug 22 ’25 when 0.17 million shares were sold. Director, Schwab Andrew J. completed a deal on Aug 21 ’25 to sell 60956.0 shares. Meanwhile, 10% Owner 5AM Partners VII, LLC sold 0.17 million shares on Aug 22 ’25.
